Immix Biopharma, Inc. (IMMX) vs Nuvectis Pharma, Inc. (NVCT)
A side-by-side comparison of Immix Biopharma, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMMX
Immix Biopharma, Inc.
$9.69HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
NVCT
Nuvectis Pharma, Inc.
$20.53HealthcareDelayed quote: Oct 6, 2026, 12:49 PM EDT
Total return — IMMX vs NVCT
growth of $100 · dividends reinvested · last 5yIMMX +131.8% (+18.3%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
IMMX NVCT
IMMX vs NVCT: by the numbers
- •NVCT is the larger company ($545M vs $527M market cap).
Metrics side by side
Valuation
| Metric | IMMX | NVCT |
|---|---|---|
| P/B ratio | 2.30 | 59.99 |
Profitability
| Metric | IMMX | NVCT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -17.44% | -306.61% |
| ROIC | -18.20% | -317.86% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.